How much does a course of selumetinib cost?

In the Chinese market, the original drug selumetinib is marketed under the name Selumetinib and has been included in the medical insurance directory to provide certain financial support for neurofibromatosis patients. Common specifications include10mg 60 tablets and 25mg 60 tablets. The price per box is about more than 20,000 yuan. The specific price will vary depending on the region, hospital procurement policy and medical insurance reimbursement ratio. Since selumetinib is an oral targeted drug, its single dose and course dosage will be individually adjusted based on the patient's weight, age, and disease severity, so the actual cost of a course of treatment may vary.

Usually, the dosage for a complete course of treatment in clinical practice is calculated in units of 28 days. The recommended dosage for children and adults is different. Doctors will adjust the dosage based on body surface area and drug tolerance. It should be noted that since selumetinib is a long-term oral drug, the course of treatment may last for months or even years to maintain efficacy and control disease progression, so the cumulative cost may be higher. This is also the main reason why many patients are concerned about drug prices and medical insurance reimbursement policies.

In overseas markets, the price of the original drug selumetinib is also high. For example, in some regions of Europe and the United States, the price per box is approximately RMB 50,000, but the specific price fluctuates greatly due to exchange rates and market policies. Since the drug has been covered by domestic medical insurance, the actual out-of-pocket amount paid by the patient is usually lower than the full drug cost, but it is still necessary to consult the hospital pharmacy according to the personal medical insurance reimbursement policy to ensure that the final cost is understood.

In addition, as a drug for rare diseases, the price of selumetinib reflects factors such as high research and development costs, limited patient groups for indications, and complex production processes. Pharmaceutical companies need to take into account R&D investment recovery and patient affordability when setting prices, which is one of the reasons why drug prices remain high.

Reference materials:https://www.koselugo.com